.jpeg)
An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who’ve failed other medications, a new trial shows. The treatment, tulisokibart, spurred remission of symptoms in more than a quarter of patients, compared to only 1.5% of those taking a placebo, an international group of researchers reported Sept. 26 in… read on > read on >